Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.

@article{ThussPatience2005DocetaxelAC,
  title={Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.},
  author={Peter C. Thuss-Patience and Albrecht Kretzschmar and Michael Repp and Dorothea Kingreen and Dirk Hennesser and Simone Micheel and Daniel Pink and Christian Scholz and Bernd Doerken and Peter Reichardt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 3},
  pages={494-501}
}
PURPOSE A combination of docetaxel and fluorouracil (DF) was evaluated in an outpatient setting and compared with epirubicin, cisplatin, and fluorouracil (ECF), which served as an internal control arm to avoid selection bias. PATIENTS AND METHODS Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.

Asian Pacific journal of cancer prevention : APJCP • 2013
View 11 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…